Nothing Benign About It: BPH Drugs' Bids For Prostate Cancer Risk Reduction Voted Down By Advisory Committee

Reducing the risk of low-grade prostate cancers that may not affect a patient's health isn't worth the risk of increasing the numbers of high-grade tumors, ODAC says.